AIM: To assess whether gemcitabine-based combination therapy improves the prognosis of unresectable pancreatic cancer compared with gemcitabine treatment alone. METHODS: A quantitative up-to-date meta-analysis was undertaken to investigate the efficacy of gemcitabine-based combination treatment compared with gemcitabine monotherapy in locally advanced or metastatic pancreatic cancer. Inclusion was limited to high-quality randomized clinical trials. RESULTS: Twenty-six studies were included in the present analysis, with a total of 8808 patients recruited. The studies were divided into four subgroups based on the different kinds of cytotoxic agents, including platinum, fluoropyrimidine, camptothecin and targeted agents. Patients treated with gemcitabine monotherapy had significantly lower objective response rate [risk ratio (RR), 0.72; 95% confidence interval (CI): 0.63-0.83; P < 0.001], and lower 1-year overall survival (RR, 0.90; 95%CI: 0.82-0.99; P = 0.04). Gemcitabine monotherapy caused fewer complications, including fewer grade 3-4 toxicities: including vomiting (RR, 0.75; 95%CI: 0.62-0.89; P = 0.001), diarrhea (RR, 0.66; 95%CI: 0.49-0.89; P = 0.006), neutropenia (RR, 0.88; 95%CI: 0.72-1.06; P = 0.18), anemia (RR, 0.96; 95%CI: 0.82-1.12; P = 0.60), and thrombocytopenia (RR, 0.76; 95%CI: 0.60-0.97; P = 0.03) compared with gemcitabine combination therapies. CONCLUSION: Gemcitabine combination therapy provides a modest improvement of survival, but is associated with more toxicity compared with gemcitabine monotherapy.
AIM: To assess whether gemcitabine-based combination therapy improves the prognosis of unresectable pancreatic cancer compared with gemcitabine treatment alone. METHODS: A quantitative up-to-date meta-analysis was undertaken to investigate the efficacy of gemcitabine-based combination treatment compared with gemcitabine monotherapy in locally advanced or metastatic pancreatic cancer. Inclusion was limited to high-quality randomized clinical trials. RESULTS: Twenty-six studies were included in the present analysis, with a total of 8808 patients recruited. The studies were divided into four subgroups based on the different kinds of cytotoxic agents, including platinum, fluoropyrimidine, camptothecin and targeted agents. Patients treated with gemcitabine monotherapy had significantly lower objective response rate [risk ratio (RR), 0.72; 95% confidence interval (CI): 0.63-0.83; P < 0.001], and lower 1-year overall survival (RR, 0.90; 95%CI: 0.82-0.99; P = 0.04). Gemcitabine monotherapy caused fewer complications, including fewer grade 3-4 toxicities: including vomiting (RR, 0.75; 95%CI: 0.62-0.89; P = 0.001), diarrhea (RR, 0.66; 95%CI: 0.49-0.89; P = 0.006), neutropenia (RR, 0.88; 95%CI: 0.72-1.06; P = 0.18), anemia (RR, 0.96; 95%CI: 0.82-1.12; P = 0.60), and thrombocytopenia (RR, 0.76; 95%CI: 0.60-0.97; P = 0.03) compared with gemcitabine combination therapies. CONCLUSION:Gemcitabine combination therapy provides a modest improvement of survival, but is associated with more toxicity compared with gemcitabine monotherapy.
Entities:
Keywords:
Combination therapy; Gemcitabine; Meta-analysis; Outcome; Pancreatic cancer
Authors: W Scheithauer; B Schüll; H Ulrich-Pur; K Schmid; M Raderer; K Haider; W Kwasny; D Depisch; B Schneeweiss; F Lang; G V Kornek Journal: Ann Oncol Date: 2003-01 Impact factor: 32.976
Authors: E Van Cutsem; H van de Velde; P Karasek; H Oettle; W L Vervenne; A Szawlowski; P Schoffski; S Post; C Verslype; H Neumann; H Safran; Y Humblet; J Perez Ruixo; Y Ma; D Von Hoff Journal: J Clin Oncol Date: 2004-04-15 Impact factor: 44.544
Authors: Jordan D Berlin; Paul Catalano; James P Thomas; John W Kugler; Daniel G Haller; Al Bowen Benson Journal: J Clin Oncol Date: 2002-08-01 Impact factor: 44.544
Authors: Caio M Rocha Lima; Mark R Green; Robert Rotche; Wilson H Miller; G Mark Jeffrey; Laura A Cisar; Adele Morganti; Nicoletta Orlando; Gabriela Gruia; Langdon L Miller Journal: J Clin Oncol Date: 2004-09-15 Impact factor: 44.544
Authors: Johanna K Morales; Sheinei J Saleem; Rebecca K Martin; Bryan L Saunders; Brian O Barnstein; Travis W Faber; Nicholas A Pullen; Elizabeth Motunrayo Kolawole; Keith B Brooks; Sarah K Norton; Jamie Sturgill; Laura Graham; Harry D Bear; Joseph F Urban; Chris S Lantz; Daniel H Conrad; John J Ryan Journal: J Leukoc Biol Date: 2013-12-12 Impact factor: 4.962
Authors: Dannel Yeo; Nhi Huynh; John A Beutler; Graham S Baldwin; Hong He; Mehrdad Nikfarjam Journal: J Invest Surg Date: 2016-03-30 Impact factor: 2.533
Authors: Dannel Yeo; Nhi Huynh; John A Beutler; Christopher Christophi; Arthur Shulkes; Graham S Baldwin; Mehrdad Nikfarjam; Hong He Journal: Cancer Lett Date: 2014-01-31 Impact factor: 8.679